A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Willingness to provide signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization

Age ≥ 50 years

For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study

Although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch. A patient's primary care physician, obstetrician, or gynecologist should be consulted regarding an appropriate form of birth control.

Ability and willingness to return for all scheduled visits and assessments

Study eyes must meet the following criteria for entry into the SAVE trial:

The last treatment with Ranibizumab is ≥ 28 days

To have received at least 9 injections of Ranibizumab in the past 12 months

Any CNVM lesion (Occult, Minimally Classic or Classic) (i.e., leakage on fluorescein angiography or subretinal, intraretinal, or sub-RPE fluid on Spectral Domain OCT) secondary to age-related macular degeneration.

Best corrected visual acuity in the study eye, using e-ETDRS testing, between 20/25 and 20/320 (Snellen equivalent), inclusive.

Only one eye will be enrolled in the Study. If both eyes are eligible study investigator will select the eye for entry.

The total area of subretinal hemorrhage and fibrosis must comprise less than 50% of the total lesion.

Clear ocular media and adequate pupillary dilation to permit good quality fundus imaging

Atrial fibrillation not managed by patient's primary care physician or cardiologist within 3 months of screening visit

A woman is considered not to be of childbearing potential if she is postmenopausal, defined by amenorrhea for at least 1 year in a woman \> 45 years old; or has undergone hysterectomy and/or bilateral oophorectomy.

History of stroke within the last 3 months of screening visit

History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications

Current treatment for active systemic infection

Active malignancy

History of allergy to fluorescein, not amenable to treatment

Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center

Inability to comply with study or follow-up procedures

Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)

What this study is about